Pharma BD Deal Intelligence

Nestle S.A. / Allergan plc

2020 · Asset Purchase · Complete

Announcement Sentiment

Positive

As part of FTC clearance for AbbVie's Allergan acquisition, Allergan divested pancreatic enzyme replacement therapies Zenpep and Viokace to Nestle Health Science. Terms not disclosed; deal completed alongside AbbVie/Allergan close.

Did it work? Outcome assessment

Strategic verdict

Achieved Stated Rationale

Pipeline outcome

Assets Advanced

Assessment window: 5yr post-close.

Key facts

Announced Jan 27, 2020
Closed May 08, 2020
Deal type Asset Purchase
Therapeutic area Exocrine pancreatic insufficiency
Indications Exocrine pancreatic insufficiency
Key assets Zenpep; Viokace
Mechanism Pancreatic enzyme replacement therapy

See the full interactive analysis, sources & comparables →

← Browse all deals · How we score deals